Loading...
Market
Will Genentech's oncology pipeline achieve projected peak sales of $3.6 billion by December 31, 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Genentech's financial reports and earnings statements
Story
Genentech Acquires Regor's CDK Inhibitors in Definitive Purchase Agreement for $850M
Sep 30, 2024, 11:05 AM
Genentech has announced the acquisition of Regor's portfolio of next-generation CDK inhibitors for $850 million upfront, with potential additional milestone payments. This acquisition includes CDK inhibitors such as RGT-4198, which is in phase 1 and targets CDK4/2/6 with some CDK9 activity. The deal is part of a Definitive Purchase Agreement and is expected to enhance Genentech's oncology pipeline, particularly in the treatment of breast cancer. Roche, the parent company of Genentech, is also projecting more than 3 billion Swiss francs ($3.6 billion) in peak sales from its drug candidates in obesity and diabetes, acquired from Carmot Therapeutics.
View original story
Similar markets
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Yes • 50%
No • 50%
Significant progress • 25%
Moderate progress • 25%
Little progress • 25%
No progress • 25%
Below $5 billion • 25%
$5 billion to $5.5 billion • 25%
$5.5 billion to $6 billion • 25%
Above $6 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
